FDA Approves First New Gonorrhea Treatments in 30 Years | Oral Antibiotics Available Now

For the first time in over three decades, new treatment options are available for gonorrhea, a common sexually transmitted infection. The U.S. Food and Drug Administration (FDA) recently approved two novel antibiotics – gepotidacin, marketed as Blujepa, and zoliflodacin, sold as Nuzolvence – offering a crucial step forward in combating rising antibiotic resistance. These approvals come as the World Health Organization (WHO) continues to raise concerns about the increasing prevalence of drug-resistant gonorrhea globally.

Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, affects an estimated 82 million people worldwide annually, with approximately 1.6 million cases reported in the United States each year, according to the Centers for Disease Control and Prevention (CDC). Many infections are asymptomatic, meaning individuals may unknowingly transmit the bacteria. Untreated gonorrhea can lead to serious health complications, including infertility in both men and women.

The Growing Challenge of Antibiotic Resistance

The emergence of antibiotic-resistant strains of gonorrhea has significantly complicated treatment efforts. Historically, the bacteria have developed resistance to a range of antibiotics, including sulfanilamides, penicillins, tetracyclines, and fluoroquinolones. Currently, ceftriaxone, a cephalosporin antibiotic administered via injection, remains the primary recommended treatment. Although, even ceftriaxone’s effectiveness is being threatened, prompting the urgent need for new therapeutic options.

Both gepotidacin and zoliflodacin represent a new class of antibiotics, offering a mechanism of action distinct from those to which the bacteria have already developed resistance. Importantly, both drugs are administered orally, simplifying treatment and improving accessibility compared to injectable medications.

Blujepa (Gepotidacin): A Dual-Purpose Antibiotic

Gepotidacin, now available under the brand name Blujepa, was initially approved in March 2026 for the treatment of uncomplicated urinary tract infections. Its subsequent approval for gonorrhea provides a versatile option for clinicians. A standard course of treatment involves eight pills taken in two doses.

Clinical trial data, involving 628 patients, demonstrated comparable efficacy to the current standard treatment. Specifically, 93% of patients treated with Blujepa achieved a cure, compared to 91% of those receiving ceftriaxone injection followed by a single dose of azithromycin. While patients taking Blujepa reported a higher incidence of side effects, such as diarrhea and nausea, these were generally mild in nature. More information about gepotidacin can be found on the FDA’s website.

Nuzolvence (Zoliflodacin): Targeted Treatment for Gonorrhea

Zoliflodacin, marketed as Nuzolvence, is administered as a single dose, dissolving in water for oral consumption. Research indicates similar cure rates to existing treatments. A study of 930 patients showed that 91% were cured one week after receiving Nuzolvence, compared to 96% of patients who received the standard ceftriaxone and azithromycin regimen.

Nuzolvence’s development is particularly noteworthy. It was a collaborative effort between the Global Antibiotic Research and Development Partnership (GARDP), a non-profit organization established by the WHO, and Innoviva Specialty Therapeutics. GARDP’s mission is to foster the development of new antibiotics, recognizing the limited financial incentives for pharmaceutical companies to invest in these crucial medications. This partnership highlights a novel approach to addressing the global threat of antibiotic resistance.

A deliberate strategy guided Nuzolvence’s development: It’s specifically intended for the treatment of gonorrhea, aiming to prevent overuse and minimize the potential for further resistance development. This focused approach is a key element in preserving the drug’s effectiveness over time.

Expert Perspectives and the Path Forward

Public health experts have expressed considerable enthusiasm for these new treatment options. Edward Hook, MD, emeritus professor of medicine at the University of Alabama and former ASHA board member, emphasized the significance of these approvals, stating, “It’s been more than 30 years since the FDA approved a new antibiotic for gonorrhea treatment. At a time when antibiotic resistance is increasing worldwide, having new oral antibiotics effective against antibiotic resistant gonorrhea is a great addition to care for persons with an at risk for STIs.”

The approval of gepotidacin and zoliflodacin represents a vital step in addressing the growing challenge of antibiotic-resistant gonorrhea. However, ongoing surveillance and research are crucial to monitor the effectiveness of these new treatments and to identify any emerging resistance patterns. The CDC continues to track gonorrhea rates and resistance trends through its Sexually Transmitted Disease Surveillance Report, providing essential data for public health interventions.

Looking ahead, continued investment in antibiotic research and development, coupled with responsible antibiotic stewardship practices, will be essential to safeguard against the spread of drug-resistant gonorrhea and protect public health. Individuals concerned about potential exposure to gonorrhea should consult with a healthcare provider for testing and appropriate treatment. For more information about gonorrhea and other STIs, resources are available from organizations like the American Sexual Health Association (ASHA).

The FDA and WHO will continue to review data on these new treatments and monitor their impact on gonorrhea infection rates and antibiotic resistance patterns. Further research may explore optimal treatment regimens and identify potential strategies to prevent the emergence of resistance to these novel antibiotics.